Report
Nitin Agarwal

Event update: Natco Pharma (Outperformer) - Strategic innovation continues

Event

Over the last few days, Natco has made a couple of announcements which are interesting from a strategic perspective even though the near term financial impact may be limited

Key highlights

  • Launch of generic Valsartan / Sacubitril tablets - generic version of Novartis’ relatively new cardiac drug Ernesto – in India
  • Management has indicated that currently Novartis sells the drug on its own as well as through a couple of partners; current sales are >Rs1bn. There are a couple of patents protecting Ernesto in India but the Natco mgt feels that it can prevail, if litigated.
  • The company believes that if the market doesn’t get crowded with follow-on generic launches over the next few months, this could well be Natco’s first big launch in the CnD (Cardio and Diabetes space).
  • Secondly, recently Natco has announced an interesting diversification looking   to enter agrochemical segment. For this it has outlined a capex outlay of Rs1bn looking to set up a greenfield facility for both agrochemical technical as well as formulation. The facility is expected to be ready by 2019-end.
  • Mgt perspective is that a general lack of R&D focus amongst current participants in the agrochem market provides an opportunity for potential disruptors like Natco who can leverage their R&D and regulatory capabilities to create some attractive opportunities by leveraging gaps in the patent landscape etc.
  • Mgt believes that if it plays out as expected, agrochemical could be meaningful opportunity for the company in next 3-4 years

Valuations & view

Given their unconventional nature, we believe that the outcome / degree of success of Natco’s these two initiatives is hard to predict. However, given the increasing competitiveness of the typical generics business model, we believe that such “out of box” strategic thinking – strategic innovation will be increasingly key to success for Indian pharma players. In our view, Natco’s business strategy is broadly in-line with this thought process which differentiates it from most Indian peers. Overall, with proven R&D capabilities post successful launches of multiple complex generics and a much stronger balance sheet, Natco has now created a strong platform to make relatively aggressive investments (versus the past) to move into the next growth orbit. While earnings may be flattish over FY19-21E, anticipated launches of gRevlimid and gNexavar etc., accompanied with the scale-up in India and RoW markets will keep up the earnings momentum over the next 3-5 years. Maintain Outperformer.

Underlying
Natco Pharma Ltd.

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The Company's product categories include Domestic Formulations, International Formulations, API's and Blockbusters. The Company's products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract.

Provider
IDFC Securities
IDFC Securities

IDFC Securities Ltd., a subsidiary of the Infrastructure Development Finance Company (IDFC) wherein the Government of India holds a 20% interest, is India's leading equities broker catering to most of the prominent financial institutions,  both foreign and domestic investing in Indian equities. A research team of experienced and dedicated experts ensures the flow of critically investigated stock ideas and portfolio strategies for our clients. Our coverage spans across various growth sectors such as agriculture, automobiles, Consumer Goods, Technology, Healthcare, Infrastructure, Media, Power, Real Estate, Telecom, Capital Goods, Logistics, Cement  amongst other sectors. Our clients value us for our strong research-led investment ideas, superior client servicing track record and exceptional execution skills.

Analysts
Nitin Agarwal

Other Reports on these Companies
Other Reports from IDFC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch